Eli Lilly & Co. (LLY) Stock Price

LLYStock
$1174.61+60.47%52W
Market Cap$1.05T
P/E55.87x
PEG Ratio1.48
Div yield0.75%
Beta0.45

LLY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)0.78%
Price vs S&P 500 (4W)3.21%
PEG Ratio1.48
VGM Score52.58
P/E Ratio (Annual)55.87x
Indicated Dividend Yield (Annual)0.75%

LLY Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026$6.58$8.38+27.27%(+$1.80)
Q1 2026$6.79$8.55+25.90%(+$1.76)
Q4 2025$6.91$7.54+9.14%(+$0.63)
Q3 2025$5.89$7.02+19.15%(+$1.13)
Q2 2025$5.59$6.31+12.89%(+$0.72)

LLY Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.03
4.05
4.05
4.05

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
LLYEli Lilly & Co.
DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69
BMYBristol-Myers Squibb Co.BBB$66.58

About Eli Lilly & Co.

Eli Lilly is a pharmaceutical company with leading therapeutic portfolios in neuroscience, cardiometabolic disease, cancer, and immunology. The company's key franchises include blockbuster diabetes and obesity treatments (Mounjaro, Zepbound, Jardiance, Trulicity), foundational insulin products (Humalog, Humulin), the cancer therapy Verzenio, and immunology treatments (Taltz, Olumiant).